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1. Introduction 
In the field of glioma research, in vitro models are widely used to investigate tumor biology 
as well as tumor response to chemotherapy and radiation. There is an increasing need to 
improve these in vitro models in order to meet the new challenges arising in drug discovery. 
It is thus important that development of new drugs is based on the latest knowledge about 
glioma biology such as for example the recent discovery of tumor stem cells (Reya et al., 
2001). When investigating glioblastomas in vitro – and especially the supposed tumor stem 
cells – three dimensional multicellular spheroid models have recently come into focus.  
The aim of this chapter is to review the development as well as the most recent aspects of 
the three-dimensional glioma in vitro models focusing on glioma spheroids. The 
implementation of these models in current and in future in vitro glioma research will be 
discussed putting emphasis on the themes described below. 
Cell lines cultured as monolayers have been the in vitro model of choice for many years 
(Ponten & Macintyre, 1968). However, the three-dimensional aspect came into focus in the 
1970’s, where scientists started to grow tumor cells from cell lines as multicellular spheroids 
(Yuhas et al., 1977). Over the years the spheroid model has been improved by deriving 
spheroids from cells obtained from dissociated primary glioblastoma tissue (Mackillop et al., 
1985) as well as by using organotypic primary spheroids derived from small tumor 
fragments (Bjerkvig et al., 1990).  
In general, most in vitro studies are performed with cells cultured in conventional serum-
containing medium. Recently – as the tumor stem cell theory has evolved – the culturing 
medium has come into focus. It has thus been demonstrated that the use of serum-free 
medium for culturing of cell line-derived spheroids preserved the in vivo-like features as 
well as the tumor stem cell-like phenotype suggesting crucial importance of the use of 
serum-free medium in tumor stem cell research (Lee et al., 2006).  
Identification of the glioma stem cells is still a matter of discussion. The most used marker in 
the field has been the cell surface marker CD133. Expression of this putative tumor stem cell 
marker in gliomas has been studied in several papers demonstrating clusters or niches of 
CD133 positive tumor cells as well as CD133 positive single cells dispersed in the tumor 
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(Christensen et al., 2008; Hermansen et al., 2011). These important tumor stem cell niches are 
preserved in primary glioma spheroids in contrast to cell line spheroids (Christensen et al., 
2010).  
Another important aspect in culturing of glioma stem cells is hypoxia, since several studies 
have shown that hypoxia influences radiation resistance. This may be explained by effects of 
hypoxia in vitro on proliferation of the tumor cells, spheroid formation and expression of 
stem cell markers, suggesting that also this aspect should be taken into consideration 
(Heddleston et al., 2009; Kolenda et al., 2010; McCord et al., 2009; Soeda et al., 2009). 
Several studies have used the different types of spheroids mentioned above for investigating 
the effects of chemotherapy and radiation on the tumor cells and in particular on the tumor 
stem-like cells (Bao et al., 2006; Bauman et al., 1999; Fehlauer et al., 2005; Fehlauer et al., 
2006; Fehlauer et al., 2007; Genc et al., 2004; Gliemroth et al., 2003; Haas-Kogan et al., 1996; 
Johannessen et al., 2009; Kaaijk et al., 1997; Khaitan et al., 2009; Sunayama et al., 2010; Terzis 
et al., 1997; Terzis et al., 1998; Wakimoto et al., 2009; Wang et al., 2010). After such 
treatments cell viability and cell proliferation assays as well as secondary spheroid 
formation assays have been used to evaluate induced effects. Moreover, expression of 
apoptosis and proliferation markers and for example stem cell markers have been 
investigated immunohistochemically in paraffin embedded spheroids (Christensen et al., 
2010). The advantages using this panel of methods will be an important part of this chapter. 
High grade gliomas are known to be highly invasive and new knowledge concerning tumor 
cell invasion also incorporating the tumor stem cell aspect is urgently needed. In our 
laboratory we have worked to improve in vitro models when investigating the invasive 
features of gliomas. This led to establishment of an in vivo-like model of invasion, where 
spheroids are implanted into organotypic brain slice cultures. 
Taken together the three-dimensional multicellular spheroid model is the three dimensional 
model of choice for in vivo-like glioma in vitro studies. However, at the same time this 
model is under ongoing development to become an even more in vivo-like model in order 
to meet the new challenges of glioma research and drug development. The use of spheroids 
in especially tumor stem cell research has been fast increasing in recent years making 
spheroids an important tool also in future glioma research. 
2. Establishment and development of the spheroid model 
In the field of cancer research it is important to continuously develop in vitro models 
mimicking in vivo conditions as much as possible. By isolating cells from tumor tissue, 
tumor cell lines can be established from almost any kind of tumor including brain tumors 
such as glioblastomas. Glioblastoma cell lines are traditionally cultured as adherent 
monolayers but can also be cultured as single cell suspensions or spheroids. One of the most 
used cell lines in glioblastoma research is the cell line U87MG established by Pontén and 
Macintyre in 1968 (Ponten & Macintyre, 1968). This cell line was established from an 
astrocytic tumor with necrosis, which corresponds to this tumor being a glioblastoma 
multiforme according to WHO (World Health Organization) guidelines 2007 (Louis et al. 
2007). U87MG was originally established in a traditional serum containing medium and the 
cells were described as large, extremely bizarre and very slowly growing. Today U87MG 
can be described as having only limited pleomorphism as well as being fast growing, clearly 
indicating that such cell lines change over time. U87MG has been used in a variety of glioma 
studies and is still used. Since the cell line has been cultured in different laboratories for 
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over 40 years new genomic mutations have arisen capable of giving rise to different 
phenotypic subpopulations in different laboratories. It is also well known that the 
phenotypic characteristics and genetic aberrations found within in vitro cells passaged 
repeatedly for about 10 times in serum containing medium often show only little 
resemblance with the original primary tumor (Lee et al., 2006). It is therefore not surprising 
that the U87MG cell line is known to have a highly aberrant genomic structure as visualized 
by karyotyping (Galli et al., 2004). Galli et al. (Galli et al., 2004) demonstrated loss of 
chromosome 1, 9, 10, 11, 12, 13, 14, 16, 19, 20, 22 and X. Furthermore, 11 unidentified 
abnormal chromosomes were found, whereas no gains of chromosomes were seen. In 
addition to this, Clark et al (Clark et al., 2010) have sequenced the genome of U87MG in 
order to further characterize it. They identified 35 interchromosomal translocation events, 
1,315 structural variations (>100 bp), 191,743 small (< 21 bp) insertions and deletions as well 
as 2,384,470 single nucleotide variations. Protein coding sequences were disrupted 
predominantly by small insertions and deletions as well as larger deletions and 
translocations and 512 genes were homozygously mutated. Surprisingly, the study by Clark 
et al. also indicated that although this U87MG cell line has been cultured for more than 40 
years, the cell line has now been relatively stable for years and is not rapidly changing 
anymore. This relative stability could be an advantage when using the U87MG cell line. In 
addition, the use of this cell line for four decades has resulted in a very well characterized 
cell line. 
In general, there are many advantages when using cell lines. When first established, they are 
easy to handle in the laboratory and a large number of cells can be obtained in a short 
period of time, making it feasible to conduct large scale studies. In addition, cell lines are 
relatively easy to manipulate genetically by transfection and knock-down etc. establishing 
subpopulations with specific gene expression. These cell lines are important tools in the field 
of basic research investigating cellular pathways involved in tumor biology and response to 
different drugs. In addition to the obvious advantages, there will always be challenges when 
working with cell lines. As mentioned above, tumor cell lines are very likely to acquire new 
mutations and chromosome damage when undergoing cell division, because of the unstable 
genome in the tumor cells. The longer cultures are maintained and passaged the more 
changes accumulate (Lee et al., 2006) leading to changes in tumor cell behaviour. This is one 
of the main problems by culturing cell lines for many years. There will always be a 
possibility that the cells further mutate and several subpopulations will arise. This is 
important to keep in mind, when comparing results obtained with the same commercial cell 
line but in different laboratories at different time points.  
Another obstacle to overcome when using cell lines is the heterogeneity seen in tumors like 
glioblastomas. It is not possible to maintain the high degree of heterogeneity in long term 
cell cultures. In order to improve models using cell lines, short term cultures prepared from 
fresh tumor biopsies can be an alternative (Kolenda et al., 2010; Potter et al., 2009). The use 
of short term cultures may reduce differences between the tumor of origin and the cultured 
cells. In a study by Potter et al. (Potter et al., 2009) short term cultures from 6 pediatric 
pilocytic astrocytomas and 3 adult glioblastomas were established and cultured in 
conventional medium containing fetal calf serum. Gene expression profiles of the derived 
short term cell cultures harvested below passage 8 and their respective original biopsies 
were performed. They demonstrated that although short term cultures more resemble in 
situ gliomas than homogenous long term cultures, significant changes in gene expression 
were found between the biopsies and the derived short term cultures. The most significant 
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functions differing for the glioblastomas were associated with cell structure, shape, motility, 
proliferation, cellular development, cell death, cellular assembly and organization, cell-to-
cell signaling and interaction, as well as cell cycle. 
As our knowledge of tumor cells expands, there is a need to establish more advanced 
models to mimic the tumor in situ. One of the main problems is the fact, that the cells are 
removed from their natural environment, dissociated and cultured as single cells. It may 
therefore be important to prevent this in order to be able to mimic the natural environment 
as much as possible. Moreover in the recent years, the use of serum containing cell culturing 
medium has come into focus. The composition of serum has not been fully understood for 
many years, but it is known that it supplies the cells with nutrients, vitamins, hormones, 
and growth-, differentiation-, and attachment-factors. These factors may affect the cells in 
ways we are not fully aware of. It is also well known that there are differences between 
batches of serum (Fisher & Wieser, 1983). Another important issue is the fact that only a 
small fraction of cells in the organism is in direct contact with serum. This may be a problem 
in glioma research, since the brain and brain tumor tissues are not among these cells. In this 
context, it is also worth highlighting that neural stem cells should be cultured under serum-
free conditions similar to what has been found for the so called glioblastoma tumor stem 
cells.  
The three-dimensional glioma spheroid model came into focus in the 1970’s, where scientists 
started to grow tumor cells as multicellular spheroids using tumor cells from conventional 
monolayer cultures (Yuhas et al., 1977). Such spheroids are usually formed by aggregation 
of cells growing into the larger three-dimensional spheroids. They are believed to be a better 
model than monolayer cultures due to a three-dimensional structure with more in vivo-like 
intercellular contacts. This model was later on further improved by deriving spheroids from 
single cells obtained from dissociated primary glioblastoma tissue (Mackillop et al., 1985). In 
order to obtain an even more in vivo-like model the primary organotypic spheroids were 
introduced (Bjerkvig et al., 1990). Organotypic means that the properties characteristic of the 
tissue of origin is maintained. These spheroids are derived from freshly removed glioma 
tissue and have been shown to be a valid tumor model providing a biological system that 
mimics the original glioma in vivo.  
When deriving primary spheroids from glioma biopsies, it is important to process the tumor 
tissue as soon as it is removed. As we have published earlier (Christensen et al., 2010) the 
glioma tissue should be collected directly in the operation theatre, where the tissue is placed 
in a tube with Hanks’ Balanced Salt Solution supplemented with 0.9 % glucose and 
transported to the laboratory. The tumor tissue can then be processed according to the study 
by Bjerkvig et al. (Bjerkvig et al., 1990), where small tumor fragments of approximately 200-
400 µm in diameter are obtained after sectioning the tumor tissue manually using scalpels. 
These fragments are then transferred to 0.75% agar-coated culture flasks of 75 cm2 with pre-
warmed medium. The cultures should be kept in a standard tissue culture incubator (95% 
humidity, 95% air, and 5% CO2) and the following day the culturing medium should be 
changed in order to remove dead blood cells and cellular debris. The tumor fragments 
should then be examined under a light microscope every day, until they round up to form 
spheroids within 5-15 days.  
The main advantages by primary organotypic spheroids are the preservation of the original 
intercellular contacts and the tumor heterogeneity. However, because of this heterogeneity it 
is important to include a larger number of spheroids in in vitro studies using primary 
spheroids in order to obtain reproducible results. In a study by Bjerkvig et al., (Bjerkvig et 
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al., 1990) it was shown that when culturing small tumor fragments from astrocytic brain 
tumors of increasing grade, small primary spheroids were formed for the majority of the 
tumors within 3-5 days. The spheroids were analyzed by light microscopy as well as 
transmission- and scanning electron microscopy (TEM and SEM, respectively) after 3 and 10 
weeks of culture, showing the unique preservation of cell- to cell interaction, blood vessels, 
extracellular matrix, and macrophages. It was moreover demonstrated that the primary 
spheroids could be cultured for 70 days with preservation of the histology of the spheroids. 
In a similar study in our laboratory, glioma tissue was collected from 11 patients. The tissue 
pieces from 7 of these patients formed vital spheroids within a week. Thereafter, the 
spheroids were fixed, paraffin embedded and investigated immunohistochemically as 
described later in this chapter. Areas of necrosis were seen in some of the spheroids, 
whereas blood vessels were present in the majority of the glioma-derived spheroids.  
 
 
Fig. 1. Adherent monolayer cells and free floating spheroids. U87MG grows as an adherent 
monolayer when the cells are cultured in serum containing medium (A). However, in 
serum-free medium U87MG grows as spheroids (B). Tissue derived from freshly removed 
glioblastoma (C) and cells from a glioblastoma short term culture (D) also grow as spheroids 
when cultured in a serum-free medium. The organotypic spheroids (C) can be grown in 
serum containing medium as well and preserves in both media some of the characteristics 
found in the primary tumor such as tumor necrosis and blood vessels, whereas the short 
term culture spheroid in (D) has lost these characteristics.  
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1. Collect tissue and transport the freshly removed tumor tissue in Hanks’ Balanced Salt 
Solution supplemented with 0.9% glucose  
2. Place the tissue in a sterile petri dish  
3. Section the tumor tissue manually using two scalpels until tumor fragments  
of 50-400 µm in diameter are obtained 
4. Culture fragments in 0.75% agar coated culture flasks containing 20 ml medium 
5. Incubate the cultures in 36°C humidified air containing 5% CO2 and 95% atmospheric 
air  
6. Change the medium the next day 
7. Change the medium twice a week in 10-15 days until the fragments round up and 
form spheroids 
Box 1. Preparation of organotypic primary spheroids 
3. The tumor stem cell paradigm and the spheroid model 
The tumor stem cell paradigm proposes that only a small subset of cells – the so-called 
tumor stem cells - within the tumor cell population is able to initiate and sustain tumor 
growth (Ward & Dirks, 2007). These tumor stem cells have been found in a variety of 
different cancers such as leukaemia (Bonnet & Dick, 1997), colon cancer (Daidone et al., 
2004), breast cancer (Al-Hajj et al., 2003) and brain cancer (Singh et al., 2004). With the 
discovery of the neural stem cells (Reynolds & Weiss, 1992) it also became plausible that 
brain tumors could be derived from the transformation of neural stem cells or progenitor 
cells (Singh et al., 2004). The neural stem cells were first isolated by Reynolds and Weiss in 
1992 (Reynolds & Weiss, 1992). They found a small population of cells isolated from the 
adult striatum in mouse brain that were able to proliferate and differentiate. They cultured 
these cells in a serum-free environment supplemented with the growth factors EGF 
(epidermal growth factor) and bFGF (basic fibroblast growth factor), and the cells grew as 
neurospheres. When dissociating the neurospheres and re-plating them as single cells new 
neurospheres developed. Under these serum-free conditions most differentiating and 
differentiated cells died, whereas the neural stem cells responded to the growth factors and 
proliferated to form neurospheres (Vescovi et al., 2006). By applying the same conditions to 
human glioblastoma cells, it was possible to isolate a population of cells that formed 
tumorspheres. These cells were capable of differentiation and self-renewal (Galli et al., 2004; 
Ignatova et al., 2002; Lee et al., 2006; Singh et al., 2003). Furthermore, the cells from the 
tumorspheres gave rise to tumors resembling the primary tumor when injected into the 
brains of immunodeficient mice, suggesting that a population of the cells isolated were brain 
tumor-initiating stem-like cells. 
When culturing putative tumor stem cells, spheroid models are often used. Especially the 
clonogenic neurosphere assay is used for preserving tumor stem-like cells in serum-free 
medium (Lee et al., 2006). In this assay, primary human brain tumor tissue form spheroids 
after repeated dissociation into single cells. However, cell-to-cell interactions are interrupted 
and this might affect experimental results obtained with the tumor stem cell line-derived 
spheroids. This could be particularly important in tumor stem cell research, since the 
suggested close relationship between brain tumor stem cells and adjacent endothelial cells 
(Bao et al., 2006; Calabrese et al., 2007) is lost in these spheroids. In addition, the culturing 
medium has come into focus when performing studies focusing on tumor stem cells. As 
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mentioned earlier, normal neural stem cells are cultured under serum-free conditions, since 
it is well known that serum causes irreversible differentiation of neural stem cells (Gage et 
al., 1995). Lee et al. (Lee et al., 2006) cultured glioblastoma short term cultures in a serum-
free medium similar to the medium used for culturing neural stem cells in order to preserve 
and select for tumor stem-like cells. This serum-free medium consisted of neurobasal 
medium supplemented with EGF and bFGF, because EGF and bFGF earlier seemed to select 
for tumor stem-like cells by inducing proliferation of multipotent, self-renewing, and 
expandable tumor stem cells (Galli et al., 2004; Ignatova et al., 2002; Lee et al., 2006). In the 
study by Lee et al., (Lee et al., 2006) dissociated glioblastoma cells, cultured as short term 
cultures, formed spheroids expressing putative tumor stem cell markers but when culturing 
the selected cells in serum containing medium, they irreversibly differentiated into neural 
and glial cell lineages. Interestingly, this is in line with the irreversible differentiation of 
neural stem cells under the same conditions (Gage et al., 1995).  
In the search for improvement of in vitro models we performed a study in our laboratory 
(Christensen et al., 2010), where organotypic primary spheroids were cultured in serum-free 
medium. In terms of the tumor stem cell concept, culturing of these organotypic primary 
spheroids in serum-free conditions may be closer to the in vivo situation than using tumor 
stem cell line-derived spheroids, especially regarding studies of radiation and chemo-
sensitivity. We investigated the influence of serum-containing medium and serum-free 
medium on the phenotype of primary glioma spheroids. The aim was to elucidate whether 
serum-free medium also favors the presence of tumor cells expressing stem cell markers in 
these spheroids, when investigated immunohistochemically. The results based on seven 
malignant astrocytomas WHO Grade III–IV, supported the hypothesis that putative brain 
tumor stem cells are better preserved in serum-free culture medium with EGF and bFGF. 
When comparing spheroids from both media, we found increased CD133 expression when 
culturing primary glioma spheroids in serum-free medium compared to serum-containing 
medium, which is in line with the study by Lee et al. (Lee et al., 2006) using short term 
cultures. In contrast to Lee, who found a drastic decrease in Sox2, Bmi-1, and Nestin when 
culturing short term cultures in serum, we only found a slightly decreased expression of 
Sox2, whereas Bmi-1 and Nestin were equally expressed in both media. This better 
preservation of stem cell marker expression in serum-containing medium in primary glioma 
spheroids (Christensen et al., 2010) may be explained by primary spheroids preserving an 
intact microenvironment, whereas Lee et al. (Lee et al., 2006) repeatedly dissociated the 
spheroids. Another interesting observation was that primary glioma spheroids cultured in 
serum-free medium contained more blood vessels than in serum-containing medium, and 
furthermore, many blood vessels were hyperplastic. The immunohistochemical comparison 
showed more CD34 and VWF, but less CD31 in serum-free medium compared to serum-
containing medium. This increase was accompanied with more CD133 positive cells, thus 
suggesting that the close relationship between blood vessels and tumor stem-like cells may 
be better preserved in serum-free medium. 
As it is clear from the tumor stem cell research field, markers specific for tumor stem cells 
are of crucial importance. This has resulted in the development of a great number of 
antibodies against tumor stem cell-related proteins. Some of the most important markers in 
the field of brain tumors have been (table 1) CD133 (Bandopadhyay et al. 2010; Bidlingmaier 
et al., 2008; Christensen et al., 2008; Dell'albani, 2008; Fargeas et al., 2007; Griguer et al., 2008; 
Jaszai et al., 2007; Mizrak et al., 2008; Pfenninger et al., 2007; Wang et al., 2008; Zeppernick et 
al., 2008), A2B5 (Balik et al., 2009; Merzak et al., 1994; Ogden et al., 2008; Piepmeier et al., 
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1993; Tchoghandjian et al., 2009), Podoplanin (Goodman et al. 2009; Grau et al., 2008; 
Mishima et al., 2006; Nakamura et al., 2006; Ogasawara et al., 2008; Ordonez, 2006; 
Shibahara et al., 2006), Nestin (Dahlstrand et al., 1992a; Dahlstrand et al., 1992b; Dell'albani, 
2008; Ehrmann et al., 2005; Ma et al., 2008; Maderna et al., 2007; Strojnik et al., 2007; Wan et 
al., 2011), Mushashi-1 (Kanemura et al., 2001; Ma et al., 2008; Okano et al., 2005; Sakakibara 
& Okano, 1997; Thon et al., 2010; Toda et al., 2001), Bmi-1 (Bruggeman et al., 2007; Hayry et 
al., 2008; Park et al., 2004; Zencak et al., 2005) and Sox2 (Gangemi et al., 2009; Ma et al., 2008; 
Phi et al., 2008) and new upcoming markers such as ID1 (Kamalian et al., 2008; Maw et al., 
2009; Nam & Benezra, 2009; Schindl et al., 2001; Schindl et al., 2003; Schoppmann et al., 2003; 
Tang et al., 2009), NG2 (Brekke et al., 2006; Chekenya et al., 1999; Chekenya et al., 2002a; 
Chekenya et al., 2002b; Chekenya et al., 2008; Chekenya & Immervoll, 2007; Chekenya & 
Pilkington, 2002; Joo et al., 2008; Petrovici et al., 2010; Stallcup & Huang, 2008) and CD15 
(Capela & Temple, 2002; Capela & Temple, 2006; Read et al., 2009; Ward et al., 2009). Until 
now, the most widely used marker in brain tumors has been CD133 (Bidlingmaier et al., 
2008; Christensen et al., 2008; Dell'albani, 2008; Fargeas et al., 2007; Griguer et al., 2008; 
Jaszai et al., 2007; Mizrak et al., 2008; Pfenninger et al., 2007; Wang et al., 2008; Zeppernick et 
al., 2008).  
 
Markers Short introduction  References 
CD133 CD133 is a cell membrane glycoprotein with 
five transmembrane domains. CD133 has been 
found in a variety of non-pathogen human 
tissues including the brain. However, the 
function remains unknown. It was identified 
as a marker of hematopoietic stem cells in 1997 
and later as a marker of human neural stem 
cells. Since 2004, CD133 has been widely used 
for identifying tumor stem cells in brain 
tumors. However, some results suggest that 
CD133 is not specific for tumor stem cells. 
Downregulation of CD133 in glioma cell lines 
has been suggested to influence migration, 
spheroid formation and resistance to 
chemotherapeutics. 
Bandopadhyay et al. 2010; 
Bidlingmaier et al., 2008; 
Christensen et al., 2008; 
Dell'albani, 2008; Fargeas et 
al., 2007; Griguer et al., 2008; 
Jaszai et al., 2007; Mizrak et 
al., 2008; Pfenninger et al., 
2007; Wang et al., 2008; 
Zeppernick et al., 2008 
A2B5 A2B5 is a cell surface ganglioside found on 
white matter progenitors of the 
oligodendrocyte lineage. A2B5 has been found 
in gliomas in a population of cells, which are 
distinct from the CD133+ population but have 
the capacity to initiate tumors. A2B5 might be 
involved in glioma cell invasion in vitro, 
probably because of adhesion of the molecule 
to basement membrane components. 
Balik et al., 2009; Merzak et 
al., 1994; Ogden et al., 2008; 
Piepmeier et al., 1993; 
Tchoghandjian et al., 2009 
Podoplanin Podoplanin is a mucin-type transmembrane 
glycoprotein found in several normal tissues 
but not in mature astrocytes, oligodendrocytes 
Goodman et al. 2009; Grau et 
al., 2008; Mishima et al., 
2006; Nakamura et al., 2006; 
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Markers Short introduction  References 
or neurons. A high expression of Podoplanin 
has been found in high grade astrocytomas. 
However, no protein has been detected in 
diffuse astrocytomas or in normal brain tissue. 
Podoplanin has been suggested to be 
expressed in human glioma stem cells. This 
podoplanin positive cell population formed 
neurospheres in vitro and tumors in vivo. 
Moreover, these cells showed increased 
resistance to radiation.  
Ogasawara et al., 2008; 
Ordonez, 2006; Shibahara et 
al., 2006 
Nestin Nestin is a protein belonging to the class VI of 
intermediate filaments and it appears after 
neurulation in the CNS stem cells. In the 
normal adult brain, nestin is only expressed in 
the neural stem cells lining the ventricular wall 
and the central canal. It is believed to be a 
marker of proliferating and migrating cells. 
Nestin has been found in several tumor types 
including gliomas. The expression of nestin 
may be related to a dedifferentiated tumor 
stem cell status, enhanced cell motility, 
invasive potential and increased malignancy.  
Dahlstrand et al., 1992a; 
Dahlstrand et al., 1992b; 
Dell'albani, 2008; Ehrmann et 
al., 2005; Ma et al., 2008; 
Maderna et al., 2007; Strojnik 
et al., 2007; Wan et al., 2011 
Musashi-1 Musashi-1 belongs to a family of evolutionary 
well conserved neural RNA-binding proteins. 
Musashi-1 is found in neural stem cells and 
progenitor cells in the adult human brain and 
plays important roles in cell fate decision, 
including the maintenance of the stem cell 
state, differentiation, and tumorigenesis. 
Musashi-1 has been found in a variety of 
tumors including gliomas.  
Kanemura et al., 2001; Ma et 
al., 2008; Okano et al., 2005; 
Sakakibara & Okano, 1997; 
Thon et al., 2010; Toda et al., 
2001 
Bmi-1 Bmi-1 (B lymphoma Mo-MLV insertion region) 
is a Polycomb group transcription repressor, 
thought to be essential for self-renewal of 
neural stem cells and maintenance of the stem 
cell population by preventing premature 
senescence. Bmi-1 is found mainly around the 
ventricles in the subventricular zone and in 
vitro in cortical neural stem cells as well as in 
progenitor cells. Bmi-1 has been found to be 
highly expressed in human brain tumors 
including glioblastomas. 
Bruggeman et al., 2007; 
Hayry et al., 2008; Park et al., 
2004; Zencak et al., 2005  
Sox2 Sox2 (SRY (sex determining region Y)-box 2) is 
a transcription factor that plays a role in 
sustaining self-renewal and maintaining 
Gangemi et al., 2009;  
Ma et al., 2008;  
Phi et al., 2008 
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Markers Short introduction  References 
neuronal stem cell fate. It is found in the 
ventricular and sub-ventricular zone in fetal 
brains, but only in the ependymal cells in the 
human adult brain. It has been found to be 
highly expressed in glioblastoma cells 
compared to normal human brain and is 
believed to be involved in proliferation and 
tumorigenesis. 
ID1 ID1 (inhibitor of DNA binding 1) belongs to a 
class of transcription factors known as helix-
loop-helix (HLH) proteins. The Id gene family 
is involved in regulation of cell-cycle status 
and differentiation during embryogenesis and 
has been found in a rare type of neural stem 
cells, the B1 type, where it is necessary for self-
renewal. Expression of Id proteins has been 
demonstrated in a variety of human tumors 
including gliomas and has been investigated as 
a potential proto-oncogene. Overexpression of 
Id1 in human tumor cells induces cell 
proliferation and invasion, and also protects 
cells against drug-induced apoptosis. 
Kamalian et al., 2008; Maw et 
al., 2009; Nam & Benezra, 
2009; Schindl et al., 2001; 
Schindl et al., 2003; 
Schoppmann et al., 2003; 
Tang et al., 2009 
NG2 NG2 is a transmembrane proteoglycan that 
interacts with the ECM to mediate cell 
adhesion and proliferation. It is expressed on 
oligodendrocyte precursor cells in the adult 
CNS. It has been found in human acute 
myeloid leukemia and in gliomas, where it in 
the latter seems to increase tumor cell 
proliferation in vitro and promote 
angiogenesis in vivo.  
Brekke et al., 2006; Chekenya 
et al., 1999; Chekenya et al., 
2002a; Chekenya et al., 
2002b; Chekenya et al., 2008; 
Chekenya & Immervoll, 
2007; Chekenya & 
Pilkington, 2002; Joo et al., 
2008; Petrovici et al., 2010; 
Stallcup & Huang, 2008 
CD15 CD15 (leukocyte cluster of differentiation 15) 
also known as LeX or stage-specific embryonic 
antigen 1, SSEA-1, is an extracellular matrix-
associated carbohydrate. CD15 is secreted by 
neural progenitor cells including stem cells 
into the stem cell niche, where it binds factors 
such as WNT-1 that are important for 
progenitor proliferation and self-renewal. It is 
highly expressed on pluripotent stem cells and 
has been found in CNS germinal zones. It has 
been found in various normal tissues but also 
in different cancers including gliomas. 
Capela & Temple, 2002; 
Capela & Temple, 2006; Read 
et al., 2009; Ward et al., 2009 
Table 1. Some of the most used stem cell markers in the field of brain tumors.  
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Fig. 2. Spheroids derived from a glioblastoma short term culture were stained 
immunohistochemically with a panel of stem cell markers. After culturing, the spheroids 
were formalin fixed, paraffin embedded and sectioned in 3 µm thin sections followed by 
immunohistochemical staining. The section in (A) was stained with hematoxylin and eosin 
(HE) which is widely used in histology to identify cell nucleus and cytoplasm. Moreover, 
sections were immunohistochemically stained with the stem or tumor stem cell markers 
CD133 (B), Podoplanin (C), Nestin (D), Bmi-1 (E) and Sox2 (F).  
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CD133 was initially identified as a marker of hematopoietic stem cells in 1997 (Miraglia et 
al., 1997; Yin et al., 1997) and later as a marker of human neural stem cells (Uchida et al., 
2000). In 2003 a CD133+ subpopulation of cells with stem cell properties were isolated from 
medulloblastomas and pilocytic astrocytomas by flow cytometry (Singh et al., 2003). The 
isolated CD133+ cells formed primary neurospheres in vitro, whereas the CD133- cells did 
not. As previously mentioned, the sphere forming capability is believed to be a stem cell 
hallmark. In 2004 the same group isolated CD133+ subpopulations from medulloblastomas 
and glioblastomas and showed that they also exhibited stem cell properties in vivo. The 
CD133+ population could initiate phenotypically similar tumors, when injected 
intracranially into NOD/SCID mice in numbers as few as 100 CD133+ cells. This was not the 
case for CD133- cells, where up to 100,000 cells could not initiate new tumor formation 
(Singh et al., 2004). Although these results had a great impact on the field of glioma 
research, it should be mentioned that today controversies exist in this area. An important 
paper contributing to this controversy was a paper showing that also CD133- cells were 
tumorigenic and could give rise to CD133+ cells (Wang et al., 2008).  
In accordance with the general idea of neural stem cells residing in discrete stem cell niches 
in the adult subventricular zone (Riquelme et al., 2008; Zhu et al., 2005), we have found 
CD133+ cells in this particular zone (Hermansen et al., 2011). In line with this, 
immunohistochemical studies performed by different groups (Calabrese et al., 2007; Thon et 
al., 2010; Zeppernick et al., 2008) including our group (Christensen et al., 2008; Hermansen 
et al., 2011) have shown that CD133 is located in clusters or niches in brain tumors, some of 
which are perivascular. The size of the niches varies from large positive areas to small 
perivascular niches comprising only a few cells. Several studies, including studies from our 
group (Christensen et al., 2008; Hermansen et al., 2011; Immervoll et al., 2008) have, 
however, also reported a widespread CD133 expression pattern in areas of various normal 
tissues, which is not normally associated with stem cells. This suggests that CD133 is not 
specific for stem cells and should be used in combination with other stem or progenitor cell 
markers to isolate tumor stem cells. 
4. Hypoxia and tumor stem cells 
Several studies associate tumor hypoxia with poor patient outcome and resistance to 
therapies (Bar, 2011; Li et al., 2009; Mashiko et al., 2011). In line with this, one of the 
hallmarks of glioblastomas is the presence of necrosis, occurring as a consequence of poor 
oxygenation and nutrition because of rapid tumor growth and formation of vessel 
thrombosis (Hulleman & Helin, 2005; Louis et al., 2007; Preusser et al., 2006). The hypoxia-
inducible factors (HIFs) are transcription factors upregulated at low oxygen levels. These 
factors mediate the cellular hypoxia response influencing angiogenesis, cell survival, 
chemotherapy and radiation resistance, invasion and metastasis (Bar, 2011).  
Usually culturing of cells is performed at 21 % O2, but with the knowledge that the 
physiological oxygen concentration in the healthy brain ranges between 2.5 % and 12.5 % O2 
and in glioblastomas is even lower (Bar, 2011), it is worth considering culturing cells at 
lower oxygen concentrations. Spheroids of large sizes become hypoxic even if cultured in 
normoxia because of a diffusion gradient. However, a study by Glicklis et al. (Glicklis et al., 
2004) has described that hepatocyte spheroids with diameters up to 100 μm have a good 
oxygenation status. Other studies by Fehlauer et al. (Fehlauer et al., 2005; Fehlauer et al., 
2006; Fehlauer et al., 2007) have reported that by using glioma spheroids with diameters of 
200-250 μm, there are only few hypoxic cells and no central necrosis present. 
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Low oxygen levels in different tumor types are believed to increase the population of tumor 
stem cells and to promote a stem-like state (Bar et al., 2010; Heddleston et al., 2009; Saigusa 
et al., 2011; Soeda et al., 2009; Wang et al., 2011; Xing et al., 2011; Yeung et al., 2011). This is 
similar to results obtained for embryonic stem cells showing that low oxygen levels promote 
maintenance of pluripotent potential, and maintenance of the cells in an undifferentiated 
stem cell state (Ezashi et al., 2005; Heddleston et al., 2009). The existence of tumor stem cells 
has been suggested to be restricted to perivascular niches and hypoxic areas within the 
tumor (Heddleston et al., 2009) explaining the poor outcome and therapeutic resistance seen 
in these hypoxic tumors. In addition to obtaining a more in vivo like metabolic milieu when 
culturing cells in hypoxic conditions, hypoxia also seems to promote the existence and 
propagation of tumor stem cells (Heddleston et al., 2009; McCord et al., 2009; Seno et al., 
2009; Soeda et al., 2009). Several studies thus reported an increase in spheroid diameter, cell 
proliferation and number of spheroids (Heddleston et al., 2009; McCord et al., 2009; Soeda et 
al., 2009) when culturing spheroids in hypoxic compared to normoxic conditions. In a study 
from our group (Kolenda et al., 2010), spheroids obtained from a glioblastoma short term 
culture and the commercial glioblastoma cell line U87MG were cultured in both normoxia 
and hypoxia. Interestingly, a significant increase in the expression of the proposed stem cell 
markers CD133, Podoplanin and Bmi-1 was found in both types of spheroids when cultured 
in hypoxia. Furthermore, a study by Heddelston et al. (Heddleston et al., 2009) proposed 
that a phenotypic shift from non-stem to stem-like cells was obtained when culturing tumor 
cells in hypoxia. On the more mechanistic level, the spheroid formation in hypoxia has been 
shown to be affected by the hypoxia inducible factors as shown in studies by Li et al. (Li et 
al., 2009) and Méndez et al. (Mendez et al., 2010). Knockdown of HIF altered spheroid 
formation in glioma spheroids, resulting in smaller and fewer spheroids. Overall these 
findings suggest that culturing of cells in hypoxia as spheroids provides important in vivo-
like conditions that are optimal when studying the stem cell biology of brain tumors. 
5. Primary spheroids and radiotherapy 
In the last three decades radiotherapy has been the standard treatment or part of the 
standard treatment for newly diagnosed glioblastoma patients (Stupp et al., 2009) providing 
a significant survival benefit (Laperriere et al., 2002). However, due to resistance to the 
current treatment of a subset of cells, it remains palliative. Primary spheroids obtained from 
glioma tissue have for years been reported to be a useful model for investigating in vitro 
radiobiology due to the preserved cellular organization. Features existing in these spheroids 
such as cell-cell contact, variation in the cell cycle distribution, diffusion effects, altered 
metabolism and hypoxia may influence the outcome of treatment, contributing to a better 
resemblance of the in vivo situation than obtained with a monolayer model (Olive & 
Durand, 1994; Sutherland & Durand, 1972). One feature of particular importance in these 
spheroids is possibly the low oxygen status being partly responsible for the increased 
radioresistance of the spheroid tumor cells (Blazek et al., 2007; Hsieh et al., 2010; Sutherland, 
1998). Ionising radiation causes the formation of reactive oxygen species (ROS) (Brahme & 
Lind, 2010; 2008) and oxygen has therefore long been known to be a potent radiosensitizer 
(Vlashi et al., 2009). ROS causes damage to cellular components including DNA damage 
(Nishikawa, 2008) and are critical for irradiation-induced killing of tumor cells (Diehn et al., 
2009). However, there have also been reports of no evident correlation between hypoxia and 
radioresistance (Buffa et al., 2001; Gorlach & Acker, 1994; Sminia et al., 2003) A study by 
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Sminia et al. (Sminia et al., 2003) found that both hypoxic and well-oxygenated organotypic 
multicellular spheroids derived from glioblastoma specimens showed high resistance to 
irradiation.  
A study by Kaaijk et al. (Kaaijk et al., 1997) described the observation of only minor 
histological changes including a few shrunken nuclei, but no major histological damage in 
normoxic organotypic multicellular glioblastoma spheroids after a single dose of 50 Gy. This 
is in line with a study by Bauman et al. (Bauman et al., 1999), where C6 astrocytoma 
spheroids were implanted into a collagen type I gel. Following irradiation with 12 and 25 
Gy, neither the hypoxic core nor the rim of the spheroids experienced a significant increase 
in the fraction of apoptotic cells. Similar to this, U87MG monolayer cultures irradiated with 
8 and 20 Gy showed no considerable apoptosis five days after treatment and remained 
viable ten weeks after a 40 Gy dose was administered. However, in fact Kaaijk et al. 
reported that proliferation in three investigated organotypic multicellular spheroids was 
decreased 7-20 fold relative to untreated controls one week after hypofractionated radiation 
with a total of 40 Gy. Moreover, Fehlauer et al. (Fehlauer et al., 2005; Fehlauer et al., 2006) 
described in two studies a decrease in the percentage of MIB-1 positive proliferative cells in 
organotypic multicellular spheroids following irradiation with 20 Gy.  
It has also been suggested that tumor stem cells might show increased radioresistance 
compared to more differentiated cells (Bao et al., 2006; Phillips et al., 2006; Rich, 2007). Bao et 
al. (Bao et al., 2006) thus showed that CD133+ cells survived ionizing radiation better than 
CD133- cells and that the fraction of CD133+ cells was enriched in gliomas after radio-
therapy, suggesting that the CD133+ cellular population of gliomas is contributing to glioma 
radioresistance and could be the source of tumor repopulation after radiation. Liu et al. (Liu 
et al., 2006) investigated mRNA levels of various markers including BCRP1 (breast cancer 
resistance protein), MGMT (O-6-methylguanine-DNA methyltransferase), anti-apoptosis 
proteins and inhibitors of apoptosis protein families in CD133+ cells isolated by FACS. 
These markers are involved in treatment resistance and elevated mRNA levels were shown 
in CD133+ cells compared to CD133- cells. A significant degree of resistance towards 
chemotherapeutics such as temozolomide, carboplatin, paclitaxel and etoposide were 
demonstrated in the CD133+ cells (Liu et al., 2006). In line with these results Liu et al. 
showed enrichment of CD133+ cells in five recurrent gliomas when compared to the 
respective newly diagnosed tumors. Furthermore, results obtained in our laboratory have 
shown a much more pronounced reduction in the secondary spheroid formation capacity of 
irradiated spheroids derived from recently established glioma spheroids with stem cell 
characteristics compared to U87MG derived spheroids without these characteristics 
(Jakobsen et al. 2011). 
6. Spheroids and chemotherapy 
Besides irradiation and surgery, the treatment of glioblastomas consists of chemotherapy. 
Although the introduction of temozolomide as standard chemotherapeutic in 2005 (Stupp et 
al., 2005) has increased the overall patient survival, new and more efficient 
chemotherapeutics or targeted therapies are urgently needed. Here spheroids also have an 
important role to play. 
Investigations of the specific effects of chemotherapeutics and other drugs on glioma 
spheroids are often done by investigating the size and number of spheroids as well as the 
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viability and the proliferation of cells in the spheroids, including the ability of the cells to 
form secondary spheroid.  
Frequently used assays for measuring the viability of the cells after treatment is tetrazolium-
based cell proliferation assays. Several variations of this assay exists (XTT, MTT, MTS or 
WST-1) (Berridge et al., 2005), but all utilize the conversion of tetrazolium salts by active 
mitochondria into dark red formazan that can be monitored by absorbance measurements 
(Berridge et al., 2005). Usually these assays are used on adherent monolayer cultures, which 
consist of uniform cell populations. However, these assays have also been used on spheroids 
consisting of more heterogenous cell populations. In one study (Johannessen et al., 2009) the 
doxorubicin sensitivity was determined in high and low passage spheroids by a MTS-assay. 
This was done by placing one spheroid per well in a 96 well plate, measuring viability 
relative to size after incubation with doxorubicin for 96 hours. After the viability 
measurements, the spheroids were allowed to adhere to the bottom of the plastic plates 
resulting in cell migration from the spheroids. Immunostaining of the migratory cells were 
performed using the neural stem cell markers Nestin, Vimentin and Musashi-1. 
Another widely used assay is the lactate dehydrogenase assay (LDH-assay), measuring cell 
death. The LDH-assay indirectly measures plasma membrane damage, which is related to 
cell death. Due to membrane damage, LDH leaks to the culture medium, where it 
participates in the conversion of tetrazolium salts to formazan. The amount of formazan 
produced is directly proportional to the amount of LDH in the culture medium, which in 
turn is directly proportional to the number of dead or damaged cells (Korzeniewski & 
Callewaert, 1983). 
The size of spheroids after drug treatment has also been used as a measure of cell viability 
(Fehlauer et al., 2007; Johannessen et al., 2009; Khaitan et al., 2009; Yamaguchi et al., 2010). 
Khaitan et al. (Khaitan et al., 2009) investigated the effect of the glycolytic inhibitor 2-deoxy-
D-glucose on spheroids derived from a human glioma cell line by measuring the size of the 
spheroids after drug exposure. In a stem cell context, number and size of primary and 
secondary spheroids have also been widely used as measures of the self-renewal potential, 
which is one of the hallmarks of stem cells. Especially the traits that are attributable to tumor 
stem cells are of interest, as the tumor stem cell hypothesis states that the tumor stem cells 
need to be targeted specifically in order to improve cancer treatment. In the so called 
spheroid formation assays or clonogenic assays, the ability of the cells to form spheroids is 
investigated. In many studies (Sunayama et al., 2010; Wakimoto et al., 2009; Wang et al., 
2010; Zhu et al., 2010) this is primarily done after treatment of the cells, thereby 
investigating the effect of a given drug on the ability of the cells to self-renew. Different 
experimental setups have been employed using different cell densities, probably resulting in 
two different assays - one assay with high cell densities for evaluation of proliferation and 
another assay with small so-called clonal cell densities for evaluation of self-renewal or 
clonogenic capabilities of the cells. High cell densities often result in cell and spheroid fusion 
due to a high motility of the spheroids (Singec et al., 2006) and it is therefore not possible to 
investigate the self-renewal mechanism in this assay. A plating density of 20 cells/µl has 
been considered as clonal conditions in terms of neurosphere formation (Singec et al., 2006). 
In glioma studies cell densities ranging between 0.15 cells/µl to 300 cells/µl have been used 
(Kolenda et al., 2010; Sunayama et al., 2010; Wakimoto et al., 2009; Wang et al., 2010; Zhu et 
al., 2010) when studying spheroid formation.  
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7. An in vivo-like in vitro model of glioma invasion 
Gliomas are known to be highly invasive and new knowledge concerning tumor cell invasion 
also incorporating the tumor stem cell aspect is urgently needed. In our laboratory we have 
worked to improve in vitro models when investigating the invasive features of glioblastoma 
cells. This led to establishment of an in vivo-like model of invasion, where spheroids are 
implanted into organotypic brain slice cultures.  
The organotypic brain slice cultures became very popular research tools especially with the 
development of the roller-tube technique by Gähwiler in 1981 (Gahwiler, 1981) and the 
inter-face culturing method developed by Stoppini in 1991 (Stoppini et al., 1991). These 
cultures preserve many of the basic structural and connective tissue structures present in the 
tissue, when it is localized in the brain (Gahwiler, 1988). By implanting the organotypic 
spheroids into the organotypic brain slice cultures, it is possible to establish an organotypic 
spheroid-based slice-culture invasion assay, suitable for following tumor cell invasion into 
the brain tissue in vitro.  
The investigation of glioma invasion has been performed since the 1980’s but the models 
used have improved during the years. Different assays have been used to address the 
invasive capacities of the tumor cells. A frequently used migration assay allows spheroids to 
adhere to the bottom of coated plastic plates, and after a period of time the distance of 
migrating cells from the spheroid can be measured (Gliemroth et al., 2003; Narla et al., 1998; 
Terzis et al., 1997; Terzis et al., 1998). Another extensively used invasion assay is the Boyden 
or Boyden-like chamber-based assays. The Boyden chamber was first introduced by Boyden 
in order to investigate the chemotactic effect of mixtures of antibody and antigen on 
leukocytes (Boyden, 1962). The principle in the Boyden chambers is cell migration into a 
microporous membrane, often made of matrigel (Deryugina et al., 1997; Paulus & Tonn, 
1994; Schichor et al., 2005). The membrane is placed in between two medium-filled 
compartments; the upper compartment containing cells whereas the lower compartment 
may contain a chemotactic agent. After an incubation period, the cells migrating through the 
microporous membrane can be stained and counted (Chen, 2005). In a variation of the 
Boyden Chamber assay, slices of porcine white and gray matter were placed on top of a 
filter between the two compartments facilitating the cells to migrate through the porcine 
brain slice, making this assay a combination of the Boyden Chamber and the organotypic co-
culture system (Schichor et al., 2005).  
In the first real invasion studies, tissue aggregates from rat brain or chick heart were (Lund-
Johansen et al., 1990) placed next to the tumor tissue, but first with the development of the 
organotypic brain slice culture, it was possible to preserve the brain architecture and 
organization in an optimal way, thereby creating the conditions necessary for a more in 
vivo-like model of glioma invasion. Several groups have been using this model to 
investigate the invasion of glioma cell into organotypic brain slice cultures (Aaberg-Jessen et 
al. 2011; Caspani et al., 2006; De et al., 2002; Eyupoglu et al., 2005; Guillamo et al., 2009; 
Jensen et al. 2010; Matsumura et al., 2000; Ohnishi et al., 1998; Palfi et al., 2004; Stoppini et 
al., 1991). In one study using this model, invasion was shown to be associated with the 
histological type and grade of the tumor (Palfi et al., 2004) and in another study invasion 
and tumor-induced neurotoxicity was shown to be associated (Eyupoglu et al., 2005). Most 
interestingly, quantitative analysis of invasion has also been performed (De et al., 2002) 
using confocal laser scanning microscopy and a three-dimensional visualization after having 
followed invasion over several weeks (Matsumura et al., 2000). 
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Besides investigating tumor invasion into the brain tissue, the model offers several other 
applications. Guillamo et al. (Guillamo et al., 2009) investigated the invasion, proliferation 
and angiogenesis of six human malignant glioma spheroids implanted into organotypic 
brain slice cultures, when these co-cultures were treated with gefinitib. Some of the tumors 
implanted had EGFR amplifications resulting in more pronounced invasion than tumors 
without EGFR amplification. Upon treatment with gefinitib only tumor cell invasion from 
tumors with EGFR amplification was inhibited, whereas vascular density was decreased in 
all tumors. In another study, Caspani et al. (Caspani et al., 2006) used the co-culture model 
to investigate the re-organization of the cytoskeleton in migrating glioblastoma cells. Cells 
transfected with green fluorescent protein were introduced into collagen gels, brain slice 
cultures and in vivo into mice brains and the re-organization and motility of the 
glioblastoma cells in the different models were monitored by confocal microscopy.  
Organotypic brain slice cultures from rodents have been used in a variety of different 
studies using tissue obtained from different areas in the brain. The organotypic brain slice 
cultures used in the invasion studies varied from explants from spinal cord (Caspani et al., 
2006), brain slices cut in the sagittal plane (Caspani et al., 2006) and the coronal plane (De et 
al., 2002; Guillamo et al., 2009; Matsumura et al., 2000; Ohnishi et al., 1998; Palfi et al., 2004) 
as well as entorhinohippocampal slice cultures (Eyupoglu et al., 2005). Since glioblastomas 
are often located in the subcortical white matter of the cerebral hemisphere and tumor 
infiltration often extends into the adjacent cortex and through corpus callosum (Louis et al., 
2007) we have used organotypic corticostriatal brain slice cultures with cortex, striatum and 
corpus callosum for our studies of the invasive features of the glioblastoma cells. Such 
corticostriatal slice cultures should be cultured by the interface method placing the brain 
slices at the interface between air and culturing medium on a porous, transparent and low-
protein binding membrane. This allows the cultures to be oxygenated on one site, while 
receiving nutrients from the other site. In the following text our approach is described in 
details.  
The corticostriatal slice cultures are prepared from newborn Wistar rat pups by a method 
slightly modified from Kristensen et al. (Kristensen et al., 1999). The brain is aseptically 
removed from the pup and placed in a petri dish under a stereomicroscope, where the 
meninges are carefully removed. Hereafter the brain is sectioned coronally in 400 μm slices 
on a McIIwain tissue Chopper and the slices are transferred to a petri dish containing 
Hanks’ Balanced Salt Solution supplemented with 0.9% glucose. The brain slices are 
separated from each other and the sections containing cortex and striatum are divided into 
the two hemispheric parts resulting in the final brain slices. These slices are randomly 
moved to the insert membranes with four cultures on each membrane. Finally, the 
membrane inserts are placed in a 6-well plate in 1 ml preheated medium, and incubated in 
36°C humidified air containing 5% CO2 and 95% atmospheric air.  
Cell line spheroids or organotypic primary spheroids are implanted into organotypic 
brain slice cultures in the corpus callosum area between cortex and striatum, whereby a 
co-culture is established. In order to identify and follow tumor cells when they invade the 
slice, the spheroids can be labeled with the fluorescent dye, DiI (1,1′-Dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine perchlorate) for 24 h before implantation, enabling confocal 
microscopy. The labeled spheroids are prepared by adding a DiI solution to the medium 
with spheroids, achieving a concentration of 25 μg/ml. Before implantation the spheroids 
are washed in medium to avoid bringing excess dye onto the brain slice cultures. 
Spheroids around 200-400 μm in diameter are captured using a denudation pipette and 
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thereafter carefully placed next to corpus callosum between cortex and striatum in the 
brain slice cultures. The culturing plates are placed in the incubator in 36°C humidified air 
containing 5% CO2 and 95% atmospheric air, whereafter the medium is changed twice a 
week. By monitoring the co-culture with confocal time-lapse microscopy, tumor cell 
invasion into the surrounding rat brain tissue can be visualized. Using a confocal 
microscope, a z-stack can be made consisting of thin sections at different levels of the 
culture. This makes it possible to follow invasion from all parts of the spheroid in 
different layers of the brain slice culture, whereby a three-dimentional movie and image 
can be constructed or alternatively an accumulated two-dimensional image based on 
overlay of all the images from one z-stack.  
 
 
 
 
 
 
1. Decapitate a newborn rat pup 
2. Aseptically remove the brain  
3. Remove the meninges 
4. Section the brain coronally in 400 µm slices on a McIIwain tissue Chopper 
5. Separate the brain slices and choose the slices containing cortex and striatum 
6. Divide these slices into the two identical halves for obtaining the final brain slice 
cultures 
7. Move slices randomly to a transparent insert membrane  
8. Place the insert membranes in a 6-well culturing plate with 1 ml preheated medium 
9. Incubate the cultures in 36°C humidified air containing 5% CO2 and 95% atmospheric 
air 
10. Change the medium twice a week 
11. Label organotypic spheroids or spheroids derived from short term cultures with 
25µg/ml DiI for 24 h before implantation 
12. Wash the spheroids 3 times with medium before implantation  
13. Use spheroids in the size range from 200-400 µm 
14. Place the spheroids in the area between cortex and striatum next to corpus callosum 
by a denudation pipette 
15. Incubate the co-cultures in 36°C humidified air containing 5% CO2 and 95% 
atmospheric air 
16. Monitor the DiI-labeled spheroids using confocal microscopy 
 
 
 
 
 
 
Box 2. Preparation of organotypic corticostriatal brain slice cultures and implantation of 
spheroids. 
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Fig. 3. Schematic overview of the implantation of glioma spheroids into organotypic rat 
corticostriatal brain slice cultures. Glioma tissue is obtained from patients and collected in 
the operation theatre. Thereafter, it is processed and cultured in the laboratory until 
spheroids are formed. Alternatively, spheroids from established short term cultures or cell 
lines can be used. Simultaneously, brain slice cultures from newborn rats are prepared and 
cultured by the interface method. The spheroids are labeled with the fluorescent dye DiI and 
implanted into the brain slice cultures in the corpus callosum area between cortex and 
striatum, here illustrated by a phase contrast image of a spheroid immediately after 
implantation and after 14 days of culturing. Note the less marked edge of the spheroid as 
the cells migrate into the surrounding brain tissue (Cx- cortex and Str-striatum). 
www.intechopen.com
 Glioma – Exploring Its Biology and Practical Relevance 
 
392 
 
Fig. 4. Confocal images of an invasive DiI-labeled glioma spheroid implanted into an 
organotypic rat brain slice culture. The spheroid is followed by confocal timelapse 
microscopy for a period of 72 hours. The images are accumulated images based on overlay 
of all the images from one z-stack. A z-stack consists of several images obtained at different 
levels of the co-culture.  
8. Conclusion 
We conclude that the three-dimensional spheroid models offers advantages in glioma 
research taking tumor biology and microenvironment into account. Especially, when using 
the organotypic models, where the structure and organization of the tissue is preserved, 
features close to the in vivo situation are supposed to be obtained. In tumor stem cell 
research, the spheroids are a necessary tool as this culture method seems to promote the 
existence of these cells. This is especially the case when culturing the spheroids in a hypoxic 
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environment. As discussed in the chapter, spheroids have been used in a wide range of 
experiments investigating radiation responses, effects of chemotherapy and effects of 
different types of experimental drugs as well as in migration and invasion studies. The 
experimental setups may be somewhat more difficult than by using monolayer cultures, but 
since the spheroid models are supposed to be closer to the in vivo situation, the results and 
answers obtained are also supposed to be closer to what it true for the corresponding 
tumors in the human brain. However, efforts should be made to develop these three-
dimensional models to become even more in vivo-like, in order to meet new challenges in 
glioma research and drug development. The use of spheroids in especially tumor stem cell 
research has been fast increasing in recent years making spheroids an important tool also in 
future glioma research.  
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